Jared Gollob - Feb 27, 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Feb 27, 2024
Transactions value $
-$17,168
Form type
4
Date filed
2/29/2024, 04:34 PM
Previous filing
Feb 9, 2024
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $832 +400 +0.54% $2.08 75.1K Feb 27, 2024 Direct F1
transaction KYMR Common Stock Sale -$18K -400 -0.53% $45.00 74.7K Feb 27, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -400 -0.64% $0.00 62.5K Feb 27, 2024 Common Stock 400 $2.08 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.
F2 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.